相关实验视频

Updated: Jun 10, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

在晚期卵巢癌中,CDC7抑制增强了PARP抑制剂的抗瘤有效性

Shini Liu^1,2, Peng Deng^1,3, Zhaoliang Yu⁴

¹State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|October 16, 2024

概括

将细胞分裂周期7 (CDC7) 抑制剂与多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 结合起来,对卵巢癌具有前景. 这种协同方法增强了抗瘤疗效,并触发了免疫反应,克服了PARPi抵抗.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
免疫学免疫学免疫学

背景情况:

多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 对具有BRCA1/2突变的卵巢癌 (OV) 有效.
对PARPi的耐药性限制了它们的临床应用,需要新的治疗策略.
PARPi 敏感性与细胞循环功能障碍有关.

研究的目的:

确定与PARPi协同作用的新型药物,以克服卵巢癌中的耐药性.
调查细胞循环抑制剂和Olaparib之间的协同作用的机制基础.
在临床前模型中评估将CDC7抑制剂与PARPi结合的治疗潜力.

主要方法:

细胞循环激酶抑制剂库的高通量药物选.
在体外和体内研究中,将Olaparib与XL413结合起来,XL413是一种CDC7抑制剂.
评估DNA损伤,复制压力和免疫反应 (cGAS/STING通路).
在小鼠同源性瘤模型中评估抗瘤功效.

主要成果:

一种CDC7抑制剂XL413被确定为与Olaparib.com的协同作用剂.
联合治疗诱导了显著的DNA损伤和复制压力,增强了Olaparib的敏感性.
组合疗法激活了cGAS/STING信号通路,引发了I型干扰素反应.
在临床前模型中,协同治疗导致增强抗瘤免疫力和瘤回归.

结论:

将CDC7抑制剂与PARPi结合起来,代表了对晚期卵巢癌的有前途的治疗策略.
这种方法可以克服PARPi耐药性并增强抗瘤免疫力.
这些发现为对PARPi.Pi反应有限的患者提供了潜在的新治疗选择.

关键词:

这是一种CDC7抑制剂.对 PARP 抑制剂的耐药性.免疫激活系统的激活卵巢癌是发生在卵巢的癌症.针对性治疗的目标治疗.

更多相关视频

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...